$1.50
arrow_drop_down3.22%Key Stats | |
---|---|
Open | $1.60 |
Prev. Close | $1.55 |
EPS | -1.18 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $32.32M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.48 | 1.65 |
52 Week Range | 1.15 | 4.59 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.18 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday